ABSTRACT
Magnetic resonance imaging (MRI) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. MRI performs somewhat better than any of several common tests--probe to bone (PTB), erythrocyte sedimentation rate (ESR) >70 mm/hr, C-reactive protein (CRP) >14 mg/L, procalcitonin >0.3 ng/mL, and ulcer size >2 cm²--although PTB has the highest specificity of any test and is commonly used together with MRI. No studies have directly compared MRI with a combination of these tests, which may assist in diagnosis.
Subject(s)
Diabetic Foot , Magnetic Resonance Imaging , Osteomyelitis , Blood Sedimentation , C-Reactive Protein/analysis , Diabetic Foot/complications , Diabetic Foot/diagnosis , Foot/diagnostic imaging , Humans , Osteomyelitis/blood , Osteomyelitis/diagnosis , Osteomyelitis/etiology , Radiography , Sensitivity and SpecificitySubject(s)
Depression/drug therapy , Phytotherapy , Antidepressive Agents/therapeutic use , Dietary Supplements , Evidence-Based Medicine , Humans , Hypericum/adverse effects , Meta-Analysis as Topic , Phytotherapy/adverse effects , Practice Guidelines as Topic , Randomized Controlled Trials as Topic , Treatment OutcomeSubject(s)
Contraceptive Devices, Female/adverse effects , Contraceptives, Oral/adverse effects , Venous Thrombosis/etiology , Administration, Cutaneous , Contraceptive Agents, Female/administration & dosage , Contraceptive Agents, Female/adverse effects , Female , Humans , Incidence , Risk Factors , United States/epidemiology , Venous Thrombosis/epidemiologySubject(s)
Hypogonadism/drug therapy , Libido/drug effects , Sexual Dysfunction, Physiological/drug therapy , Testosterone/administration & dosage , Age Factors , Aged , Aged, 80 and over , Cross-Sectional Studies , Dose-Response Relationship, Drug , Drug Administration Schedule , Evidence-Based Medicine , Family Practice , Follow-Up Studies , Humans , Hypogonadism/diagnosis , Injections, Intramuscular , Longitudinal Studies , Male , Patient Satisfaction , Randomized Controlled Trials as Topic , Risk Assessment , Sexual Dysfunction, Physiological/diagnosis , Treatment OutcomeABSTRACT
After clinical diagnosis and microscopic confirmation, tinea cruris is best treated with a topical allylamine or an azole antifungal (strength of recommendation: A, based on multiple randomized controlled trials [RCTs]). Differences in current comparison data are insufficient to stratify the 2 groups of topical antifungals. Determining which group to use depends on patient compliance, medication accessibility, and cost. The fungicidal allylamines (naftifine and terbinafine) and butenafine (allylamine derivative) are a more costly group of topical tinea treatments, yet they are more convenient as they allow for a shorter duration of treatment compared with fungistatic azoles (clotrimazole, econazole, ketoconazole, oxiconazole, miconazole, and sulconazole).
